$Emergent BioSolutions(EBS)$ πΊππΊ
πΊππͺπ π ±ππ »π »π Έππ · πͺπΊππ
Coming out of a πͺ pattern. I opened positions and looking for a great move out of this πͺ
Source: Yahoo Finance
π Key Insights
Institutions' substantial holdings in Emergent BioSolutions implies that they have significant influence over the company's share price
A total of 25 investors have a majority stake in the company with 41% ownership
Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock
A look at the shareholders of Emergent BioSolutions Inc. (NYSE:EBS) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 53% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
Institutional investors endured the highest losses after the company's market cap fell by US$56m last week. However, the 91% one-year return to shareholders may have helped lessen their pain. They should, however, be mindful of further losses in the future.
Let's delve deeper into each type of owner of Emergent BioSolutions, beginning with the chart below.
What Does The Institutional Ownership Tell Us About Emergent BioSolutions?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
We can see that Emergent BioSolutions does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Emergent BioSolutions' earnings history below. Of course, the future is what really matters.
Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Emergent BioSolutions is not owned by hedge funds. The Vanguard Group, Inc. is currently the company's largest shareholder with 6.8% of shares outstanding. Charles Schwab Investment Management, Inc. is the second largest shareholder owning 5.9% of common stock, and BlackRock, Inc. holds about 3.6% of the company stock.
On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is some analyst coverage of the stock, but it could still become more well known, with time.
Insider Ownership Of Emergent BioSolutions
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
We can report that insiders do own shares in Emergent BioSolutions Inc.. In their own names, insiders own US$6.9m worth of stock in the US$354m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.
General Public Ownership
With a 45% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Emergent BioSolutions. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
@Tiger_comments @Daily_Discussion @TigerStars @TigerObserver @TigerPM @TigerGPT @TigerPicks
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Stock Analysis: Emergent BioSolutions Inc. (EBS)
Company Overview
Emergent BioSolutions Inc. (EBS) is a company operating in the healthcare sector, specifically focused on the development, manufacture, and distribution of medical countermeasures for biological and chemical threats. The company specializes in vaccines and therapeutics for infectious diseases, and it serves various government agencies, healthcare providers, and pharmaceutical companies.
Industry Analysis
The healthcare industry, particularly the biotechnology and pharmaceutical sectors, is expected to experience continued growth in the coming years. The demand for vaccines and medical countermeasures has increased significantly due to the global pandemic and the focus on public health preparedness. Emergent BioSolutions operates in a sector with strong growth potential.
Latest Earnings and Forecast
Earnings Result for 2024Q2:
EPS: -5.38 (USD)
Gross profit margin: -25.72%
Return on investment: -27.92%
Net profit margin: -111.15%
Earnings forecast for the next fiscal years:
2024FY:
Forecast EPS: -1.67 (USD)
Forecast gross income: 1.12B (USD)
Forecast EBIT: -82.00M (USD)
2025FY:
Forecast EPS: 2.99 (USD)
Forecast gross income: 1.20B (USD)
Forecast EBIT: -70.00M (USD)
2026FY:
Forecast EPS: 2.18 (USD)
Forecast gross income: 1.08B (USD)
Forecast EBIT: -95.00M (USD)
Stock Performance
Stock Price (As of October 22, 2024):
Current Price: 10.2129 (USD)
Support Price (October 18, 2024): 5.95 (USD)
Resistance Price (October 18, 2024): 10.03 (USD)
Average Cost (October 18, 2024): 9.53 (USD)
Profiteer Ratio (October 18, 2024): 0.5286
Analyst Recommendations and Target Price
Analyst Recommendation: 1 buy, 1 underperform
Analyst Target Price: The mean, low, and high target estimates are 8.0, 8.0, 8.0. (USD)
Capital Flow Data
5-Day Capital Flow Data:
10-14: 108.54K units (inflow)
10-15: 154.17K units (inflow)
10-16: 859.46K units (inflow)
10-17: 551.77K units (inflow)
10-18: 660.26K units (inflow)
1-Day Capital Flow Data (October 22, 2024):
Total Inflow: 672.33K
Total Outflow: 507.15K
Big Inflow: 1.74M
Median Inflow: 1.23M
Small Inflow: 3.75M
Big Outflow: 1.09M
Median Outflow: 825.93K
Small Outflow: 3.15M
Ownership Analysis
Institutional Ownership: 53%
Insider Ownership: Insiders own US$6.9M worth of stock in Emergent BioSolutions Inc.
General Public Ownership: 45%
News and Market Sentiment
Recent news sentiment: Neutral (Based on Yahoo Finance data)
Please refer to recent news and market sentiment articles for more detailed information.
Risk Disclaimer
The above analysis is for informational purposes only and should not be considered as investment advice. Investing in the stock market involves risks, and it is important to conduct thorough research and analysis before making any investment decisions. The stock price and performance can be influenced by various factors, including market conditions, industry developments, and company-specific factors. It is recommended to consult with a financial professional before making any investment decisions.
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?